UNSPSC 51361908: Hexobarbital or hexobarbitone

This classification denotes a barbiturate with the molecular formula C12H16N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AL8Z8K3P6S, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-, monosodium salt but generally known as hexobarbital, which bears US NIH Compound Identifier 3608. European Medicines Agency schedules Hexobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08038MIG. The term HEXOBARBITAL is an International Non-Proprietary Name.

UNSPSC 51361908 Hexobarbital or hexobarbitone is a Commodity code that shows minimal recent activity in state and local procurement aligned with its nominal scope. The three recent opportunities tagged under this code diverge significantly from hexobarbital or hexobarbitone procurement: Seminole County, Florida solicited naloxone and safe drug deactivation systems; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) sought generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing. None of these solicitations target barbiturate compounds specifically. State and local issuing bodies posting under this code span county health departments, state health agencies, and cooperative purchasing organizations, but the code itself does not capture a coherent product family matching current procurement activity.

Geographic activity centers on Florida, Texas, and Minnesota based on recent postings, with MMCAP serving a multi-state footprint including Oregon. The Seminole County IFB (Solicitation IFB60459723LAS, due July 26, 2023) represents the only opportunity with direct pharmaceutical procurement language, though it focused on naloxone rather than barbiturates. The Texas HHS RFI (HHS0017013, posted April 3, 2026) functions as a market-intelligence mechanism for future pharmacy benefit contracting rather than a current procurement. The MMCAP RFP (S1070000015802, due March 26, 2026) establishes cooperative contracts for generic pharmaceuticals across multiple jurisdictions but does not identify hexobarbital or hexobarbitone as a targeted product. The code shows little relevant procurement activity and does not represent active demand for the specific pharmaceutical compound it nominally describes.